Histological Scores Validate the Accuracy of Hepatic Iron Load Measured by Signal Intensity Ratio and R2* Relaxometry MRI in Dialysis Patients

Overview

Journal J Clin Med

Specialty General Medicine

Date 2019 Dec 22

PMID 31861625

Citations 9

Authors

Guy Rostoker

Mireille Laroudie

Raphael Blanc

Mireille Griuncelli

Christelle Loridon

Fanny Lepeytre

Clementine Rabate

Yves Cohen

Affiliations

Soon will be listed here.

Abstract

Almost all haemodialysis patients are treated with parenteral iron to compensate for blood loss and to allow the full therapeutic effect of erythropoiesis-stimulating agents. Iron overload is an increasingly recognised clinical situation diagnosed by quantitative magnetic resonance imaging (MRI). MRI methods have not been fully validated in dialysis patients. We compared Deugnier's and Turlin's histological scoring of iron overload and Scheuer's classification (with Perls' stain) with three quantitative MRI methods for measuring liver iron concentration (LIC)-signal intensity ratio (SIR), R2* relaxometry, and R2* multi-peak spectral modelling (Iterative Decomposition of water and fat with Echo Asymmetry and Least-squares estimation (IDEAL-IQ)) relaxometry-in 16 haemodialysis patients in whom a liver biopsy was formally indicated for medical follow-up. LIC MRI with these three different methods was highly correlated with Deugnier's and Turlin's histological scoring (SIR: = 0.8329, = 0.0002; R2* relaxometry: = -0.9099, < 0.0001; R2* relaxometry (IDEAL-IQ): = -0.872, = 0.0018). Scheuer's classification was also significantly correlated with these three MRI techniques. The positive likelihood ratio for the diagnosis of abnormal LIC by Deugnier's histological scoring was > 62 for the three MRI methods. This study supports the accuracy of quantitative MRI methods for the non-invasive diagnosis and follow-up of iron overload in haemodialysis patients.

Citing Articles

Trace and Major Element Concentrations in Cadaveric Lung Tissues from World Trade Center Health Registry Decedents and Community Controls.

Marmor M, Burcham J, Chen L, Chillrud S, Graham J, Jordan H Int J Environ Res Public Health. 2023; 20(20).

PMID: 37887662 PMC: 10606593. DOI: 10.3390/ijerph20206923.

Magnetic Resonance Imaging of Iron Metabolism with T2* Mapping Predicts an Enhanced Clinical Response to Pharmacologic Ascorbate in Patients with GBM.

Petronek M, Monga V, Bodeker K, Kwofie M, Lee C, Mapuskar K Clin Cancer Res. 2023; 30(2):283-293.

PMID: 37773633 PMC: 10841843. DOI: 10.1158/1078-0432.CCR-22-3952.

Differential Pharmacokinetics of Liver Tropism for Iron Sucrose, Ferric Carboxymaltose, and Iron Isomaltoside: A Clue to Their Safety for Dialysis Patients.

Rostoker G, Lepeytre F, Merzoug M, Griuncelli M, Loridon C, Boulahia G Pharmaceutics. 2022; 14(7).

PMID: 35890303 PMC: 9323124. DOI: 10.3390/pharmaceutics14071408.

Detection of Ferritin Expression in Soft Tissue Sarcomas With MRI: Potential Implications for Iron Metabolic Therapy.

Petronek M, Tomanek-Chalkley A, Monga V, Milhem M, Miller B, Magnotta V Iowa Orthop J. 2022; 42(1):255-262.

PMID: 35821920 PMC: 9210395.

Repeatability and Image Quality of IDEAL-IQ in Human Lumbar Vertebrae for Fat and Iron Quantification across Acquisition Parameters.

Shan B, Ding H, Lin Q, Zuo X, Lin L, Yu D Comput Math Methods Med. 2022; 2022:2229160.

PMID: 35720027 PMC: 9203175. DOI: 10.1155/2022/2229160.

References

Bailie G, Larkina M, Goodkin D, Li Y, Pisoni R, Bieber B . Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. Kidney Int. 2014; 87(1):162-8. DOI: 10.1038/ki.2014.275. View

Gandon Y, Olivie D, Guyader D, Aube C, Oberti F, Sebille V . Non-invasive assessment of hepatic iron stores by MRI. Lancet. 2004; 363(9406):357-62. DOI: 10.1016/S0140-6736(04)15436-6. View

Idilman I, Aniktar H, Idilman R, Kabacam G, Savas B, Elhan A . Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy. Radiology. 2013; 267(3):767-75. DOI: 10.1148/radiol.13121360. View

Locatelli F, Barany P, Covic A, de Francisco A, Del Vecchio L, Goldsmith D . Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant. 2013; 28(6):1346-59. DOI: 10.1093/ndt/gft033. View

Rostoker G, Griuncelli M, Loridon C, Couprie R, Benmaadi A, Bounhiol C . Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study. Am J Med. 2012; 125(10):991-999.e1. DOI: 10.1016/j.amjmed.2012.01.015. View

Rostoker G, Loridon C, Griuncelli M, Rabate C, Lepeytre F, Urena-Torres P . Liver Iron Load Influences Hepatic Fat Fraction in End-Stage Renal Disease Patients on Dialysis: A Proof of Concept Study. EBioMedicine. 2018; 39:461-471. PMC: 6354439. DOI: 10.1016/j.ebiom.2018.11.020. View

Chinnadurai R, Macdougall I, Kalra P . Treatment of anaemia in end-stage renal disease: A double-edged iron sword?. EBioMedicine. 2019; 40:31-32. PMC: 6413296. DOI: 10.1016/j.ebiom.2019.01.005. View

Eschbach J, Egrie J, Downing M, Browne J, Adamson J . Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987; 316(2):73-8. DOI: 10.1056/NEJM198701083160203. View

Deugnier Y, Turlin B . Pathology of hepatic iron overload. Semin Liver Dis. 2011; 31(3):260-71. DOI: 10.1055/s-0031-1286057. View

10.

Ghoti H, Rachmilewitz E, Simon-Lopez R, Gaber R, Katzir Z, Konen E . Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron. Eur J Haematol. 2012; 89(1):87-93. DOI: 10.1111/j.1600-0609.2012.01783.x. View

11.

Brissot P, Troadec M, Bardou-Jacquet E, Le Lan C, Jouanolle A, Deugnier Y . Current approach to hemochromatosis. Blood Rev. 2008; 22(4):195-210. DOI: 10.1016/j.blre.2008.03.001. View

12.

Rostoker G, Vaziri N . Risk of iron overload with chronic indiscriminate use of intravenous iron products in ESRD and IBD populations. Heliyon. 2019; 5(7):e02045. PMC: 6627982. DOI: 10.1016/j.heliyon.2019.e02045. View

13.

Rostoker G, Laroudie M, Blanc R, Galet B, Rabate C, Griuncelli M . Signal-intensity-ratio MRI accurately estimates hepatic iron load in hemodialysis patients. Heliyon. 2017; 3(1):e00226. PMC: 5220226. DOI: 10.1016/j.heliyon.2016.e00226. View

14.

Carpenter J, He T, Kirk P, Roughton M, Anderson L, de Noronha S . On T2* magnetic resonance and cardiac iron. Circulation. 2011; 123(14):1519-28. PMC: 3435874. DOI: 10.1161/CIRCULATIONAHA.110.007641. View

15.

Labranche R, Gilbert G, Cerny M, Vu K, Soulieres D, Olivie D . Liver Iron Quantification with MR Imaging: A Primer for Radiologists. Radiographics. 2018; 38(2):392-412. DOI: 10.1148/rg.2018170079. View

16.

Paisant A, DAssignies G, Bannier E, Bardou-Jacquet E, Gandon Y . MRI for the measurement of liver iron content, and for the diagnosis and follow-up of iron overload disorders. Presse Med. 2017; 46(12 Pt 2):e279-e287. DOI: 10.1016/j.lpm.2017.10.008. View

17.

Eschbach J, Adamson J . Iron overload in renal failure patients: changes since the introduction of erythropoietin therapy. Kidney Int Suppl. 1999; 69:S35-43. DOI: 10.1046/j.1523-1755.1999.055suppl.69035.x. View

18.

FLEMING L, Hopwood D, Shepherd A, Stewart W . Hepatic iron in dialysed patients given intravenous iron dextran. J Clin Pathol. 1990; 43(2):119-24. PMC: 502291. DOI: 10.1136/jcp.43.2.119. View

19.

Canavese C, Bergamo D, Ciccone G, Longo F, Fop F, Thea A . Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int. 2004; 65(3):1091-8. DOI: 10.1111/j.1523-1755.2004.00480.x. View

20.

Horl W . Clinical aspects of iron use in the anemia of kidney disease. J Am Soc Nephrol. 2007; 18(2):382-93. DOI: 10.1681/ASN.2006080856. View